Further validation of key results (LOH transitions, PARP1 amplifications, BRCA2 isoform switching) in an independent cohort of paired primary and recurrent BRCA1/2 mutation-associated breast and ovarian tumors will be important. The gene discussed is PARP1; the disease is ovarian neoplasm.